1. Home
  2. VVOS vs CVKD Comparison

VVOS vs CVKD Comparison

Compare VVOS & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vivos Therapeutics Inc.

VVOS

Vivos Therapeutics Inc.

HOLD

Current Price

$2.07

Market Cap

19.4M

Sector

Health Care

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$12.23

Market Cap

20.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VVOS
CVKD
Founded
2016
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
19.4M
20.7M
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
VVOS
CVKD
Price
$2.07
$12.23
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$6.25
$32.00
AVG Volume (30 Days)
123.1K
43.2K
Earning Date
11-19-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,317,000.00
N/A
Revenue This Year
$17.96
N/A
Revenue Next Year
$55.64
N/A
P/E Ratio
N/A
N/A
Revenue Growth
18.76
N/A
52 Week Low
$1.98
$8.12
52 Week High
$7.95
$22.90

Technical Indicators

Market Signals
Indicator
VVOS
CVKD
Relative Strength Index (RSI) 38.11 59.00
Support Level $1.98 $9.55
Resistance Level $2.28 $12.00
Average True Range (ATR) 0.13 0.94
MACD 0.02 0.34
Stochastic Oscillator 25.71 93.88

Price Performance

Historical Comparison
VVOS
CVKD

About VVOS Vivos Therapeutics Inc.

Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: